DK1373256T3 - CCR5-antagonister, der er nyttige til behandling af AIDS - Google Patents
CCR5-antagonister, der er nyttige til behandling af AIDSInfo
- Publication number
- DK1373256T3 DK1373256T3 DK02725381T DK02725381T DK1373256T3 DK 1373256 T3 DK1373256 T3 DK 1373256T3 DK 02725381 T DK02725381 T DK 02725381T DK 02725381 T DK02725381 T DK 02725381T DK 1373256 T3 DK1373256 T3 DK 1373256T3
- Authority
- DK
- Denmark
- Prior art keywords
- aids
- treatment
- antagonists useful
- ccr5 antagonists
- ccr5
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27993801P | 2001-03-29 | 2001-03-29 | |
| PCT/US2002/009491 WO2002079194A1 (en) | 2001-03-29 | 2002-03-27 | Ccr5 antagonists useful for treating aids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1373256T3 true DK1373256T3 (da) | 2005-10-10 |
Family
ID=23070981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02725381T DK1373256T3 (da) | 2001-03-29 | 2002-03-27 | CCR5-antagonister, der er nyttige til behandling af AIDS |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US6720325B2 (https=) |
| EP (2) | EP1373256B1 (https=) |
| JP (2) | JP4248251B2 (https=) |
| KR (1) | KR100613528B1 (https=) |
| CN (1) | CN100519554C (https=) |
| AR (1) | AR033452A1 (https=) |
| AT (2) | ATE466009T1 (https=) |
| AU (1) | AU2002255947B8 (https=) |
| BR (1) | BR0208398A (https=) |
| CA (1) | CA2442227C (https=) |
| CZ (1) | CZ20032636A3 (https=) |
| DE (2) | DE60204951T2 (https=) |
| DK (1) | DK1373256T3 (https=) |
| ES (2) | ES2242856T3 (https=) |
| HU (1) | HUP0400349A3 (https=) |
| IL (1) | IL157551A0 (https=) |
| MX (1) | MXPA03008853A (https=) |
| MY (1) | MY128609A (https=) |
| NO (1) | NO326349B1 (https=) |
| NZ (1) | NZ527768A (https=) |
| PE (1) | PE20020996A1 (https=) |
| PL (1) | PL364560A1 (https=) |
| PT (1) | PT1373256E (https=) |
| RU (1) | RU2316553C2 (https=) |
| SI (1) | SI1373256T1 (https=) |
| SK (1) | SK287521B6 (https=) |
| TW (1) | TWI237638B (https=) |
| WO (1) | WO2002079194A1 (https=) |
| ZA (1) | ZA200307474B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL364560A1 (en) * | 2001-03-29 | 2004-12-13 | Schering Corporation | Ccr5 antagonists useful for treating aids |
| KR20040013090A (ko) | 2001-07-02 | 2004-02-11 | 아스트라제네카 아베 | 케모킨 수용체 활성의 조절자로서 유용한 피페리딘 유도체 |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| TW200504033A (en) * | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
| AU2003300911A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Heterocyclic compounds as ccr5 antagonists |
| PE20040769A1 (es) | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| CN1898231B (zh) | 2003-11-03 | 2010-10-27 | 先灵公司 | 用作趋化因子受体抑制剂的双六氢吡啶衍生物 |
| EP1725235B1 (en) * | 2004-02-05 | 2009-04-15 | Schering Corporation | Piperidine derivatives useful as ccr3 antagonists |
| SE0400925D0 (sv) * | 2004-04-06 | 2004-04-06 | Astrazeneca Ab | Chemical compounds |
| BRPI0509803A (pt) * | 2004-04-13 | 2007-09-18 | Incyte Corp | derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina |
| EP1790637B1 (en) * | 2004-09-13 | 2014-01-29 | Ono Pharmaceutical Co., Ltd. | Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient |
| US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| AR052865A1 (es) * | 2005-01-06 | 2007-04-11 | Schering Corp | Preparacion de compuestos farmaceuticos derivados de sales de piperazina |
| US7728135B2 (en) * | 2005-01-06 | 2010-06-01 | Schering Corporation | Synthesis of CCR5 receptor antagonists |
| JP4769257B2 (ja) * | 2005-02-23 | 2011-09-07 | シェーリング コーポレイション | ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体 |
| EP1858886A1 (en) * | 2005-02-23 | 2007-11-28 | Schering Corporation | Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors |
| WO2007011293A1 (en) | 2005-07-21 | 2007-01-25 | Astrazeneca Ab | Novel piperidine derivatives |
| US7462485B2 (en) * | 2005-10-07 | 2008-12-09 | Glaser Lawrence F | Modified erythrocytes and uses thereof |
| TW200745087A (en) * | 2006-02-24 | 2007-12-16 | Schering Corp | CCR5 antagonists useful for treating HIV |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| US20100063280A1 (en) * | 2006-12-22 | 2010-03-11 | Schering Corporation | Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds |
| EP2259772A2 (en) * | 2008-02-29 | 2010-12-15 | Schering Corporation | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5368854A (en) | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| WO1994018192A1 (en) | 1993-02-12 | 1994-08-18 | Merck & Co., Inc. | Piperazine derivatives as hiv protease inhibitors |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| DE69623485T2 (de) | 1995-06-07 | 2003-01-09 | Kimberly-Clark Worldwide, Inc. | Inhibierung von exoprotein in absorbierenden produkten |
| NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| US5952349A (en) | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| US5977138A (en) | 1996-08-15 | 1999-11-02 | Schering Corporation | Ether muscarinic antagonists |
| WO1999004794A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| US6066636A (en) | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
| EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| CA2371583C (en) * | 1999-05-04 | 2005-09-13 | Schering Corporation | Piperazine derivatives useful as ccr5 antagonists |
| HK1039330B (en) * | 1999-05-04 | 2005-12-09 | Schering Corporation | Piperidine derivatives useful as ccr5 antagonists |
| PL364560A1 (en) * | 2001-03-29 | 2004-12-13 | Schering Corporation | Ccr5 antagonists useful for treating aids |
-
2002
- 2002-03-27 PL PL02364560A patent/PL364560A1/xx not_active IP Right Cessation
- 2002-03-27 DE DE60204951T patent/DE60204951T2/de not_active Expired - Lifetime
- 2002-03-27 SI SI200230169T patent/SI1373256T1/sl unknown
- 2002-03-27 CZ CZ20032636A patent/CZ20032636A3/cs unknown
- 2002-03-27 ES ES02725381T patent/ES2242856T3/es not_active Expired - Lifetime
- 2002-03-27 AU AU2002255947A patent/AU2002255947B8/en not_active Ceased
- 2002-03-27 CA CA002442227A patent/CA2442227C/en not_active Expired - Fee Related
- 2002-03-27 JP JP2002577819A patent/JP4248251B2/ja not_active Expired - Fee Related
- 2002-03-27 EP EP02725381A patent/EP1373256B1/en not_active Expired - Lifetime
- 2002-03-27 WO PCT/US2002/009491 patent/WO2002079194A1/en not_active Ceased
- 2002-03-27 RU RU2003131879/04A patent/RU2316553C2/ru not_active IP Right Cessation
- 2002-03-27 AR ARP020101142A patent/AR033452A1/es unknown
- 2002-03-27 AT AT05009882T patent/ATE466009T1/de not_active IP Right Cessation
- 2002-03-27 AT AT02725381T patent/ATE299139T1/de active
- 2002-03-27 US US10/107,940 patent/US6720325B2/en not_active Expired - Lifetime
- 2002-03-27 HU HU0400349A patent/HUP0400349A3/hu unknown
- 2002-03-27 MX MXPA03008853A patent/MXPA03008853A/es active IP Right Grant
- 2002-03-27 SK SK1196-2003A patent/SK287521B6/sk not_active IP Right Cessation
- 2002-03-27 KR KR1020037012565A patent/KR100613528B1/ko not_active Expired - Fee Related
- 2002-03-27 PE PE2002000251A patent/PE20020996A1/es not_active Application Discontinuation
- 2002-03-27 DK DK02725381T patent/DK1373256T3/da active
- 2002-03-27 BR BR0208398-1A patent/BR0208398A/pt not_active IP Right Cessation
- 2002-03-27 DE DE60236218T patent/DE60236218D1/de not_active Expired - Lifetime
- 2002-03-27 PT PT02725381T patent/PT1373256E/pt unknown
- 2002-03-27 EP EP05009882A patent/EP1591444B1/en not_active Expired - Lifetime
- 2002-03-27 NZ NZ527768A patent/NZ527768A/en unknown
- 2002-03-27 ES ES05009882T patent/ES2342942T3/es not_active Expired - Lifetime
- 2002-03-27 CN CNB028076540A patent/CN100519554C/zh not_active Expired - Fee Related
- 2002-03-27 IL IL15755102A patent/IL157551A0/xx not_active IP Right Cessation
- 2002-03-28 TW TW091106166A patent/TWI237638B/zh active
- 2002-03-28 MY MYPI20021140A patent/MY128609A/en unknown
-
2003
- 2003-09-25 ZA ZA200307474A patent/ZA200307474B/en unknown
- 2003-09-26 NO NO20034311A patent/NO326349B1/no not_active IP Right Cessation
-
2004
- 2004-02-06 US US10/773,521 patent/US6900211B2/en not_active Expired - Fee Related
- 2004-10-21 US US10/970,216 patent/US7008946B2/en not_active Expired - Fee Related
-
2005
- 2005-02-17 US US11/059,785 patent/US7060701B2/en not_active Expired - Fee Related
- 2005-10-14 US US11/250,247 patent/US7098213B2/en not_active Expired - Fee Related
-
2007
- 2007-10-26 JP JP2007279663A patent/JP2008074862A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1373256T3 (da) | CCR5-antagonister, der er nyttige til behandling af AIDS | |
| DK1620437T3 (da) | 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension | |
| EE200300544A (et) | 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine | |
| DK1455785T3 (da) | Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse | |
| DK1553929T3 (da) | Sammensætning med kontrolleret frigivelse. | |
| FI20010694A0 (fi) | Implantti | |
| NO20042742L (no) | Pyrimidinforbindelser | |
| FI20012426A0 (fi) | Komposiitti-nonwoven, sen käyttö ja menetelmä sen valmistamiseksi | |
| AU2003301066A8 (en) | Al2o3-la2o3-y2o3-mgo ceramics, and methods of making the same | |
| DK1421075T3 (da) | Piperidinderivater, der er nyttige som CCR5-antagonister til behandling af HIV | |
| EE200300400A (et) | Pürimidiiniühendid, nende valmistamismeetod ning kasutamine | |
| DE60224595D1 (de) | Fluoroelastomere | |
| DE60332816D1 (de) | Nk1-antagonisten | |
| DE602004012925D1 (de) | Protokoll zur Erbringung von Diensten | |
| DE60222693D1 (de) | Nk1-antagonisten | |
| DE60229463D1 (de) | Fluoroelastomere | |
| ATE418542T1 (de) | Als ccr5-antagonisten verwendbare aryloxim- piperazine | |
| HRP20080447T3 (en) | 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof | |
| DK1257278T3 (da) | Anvendelse af mirtazapin til behandling af sövnforstyrrelser | |
| DK1268482T3 (da) | Pyranoindoler til behandling af glaukom | |
| DK1461042T3 (da) | Anvendelse af desoxypeganin til behandling af klinisk depression | |
| DK1390364T3 (da) | Aryl-8-azabicyclo[3.2.1]octaner til behandling af depression | |
| DK1373232T3 (da) | Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner | |
| DK1503995T3 (da) | Fremgangsmåde til fremstilling af substituerede phenylsulfonylurinstoffer | |
| PL362793A1 (pl) | Antagoniści reseptorów histaminowych |